放射線誘発食道炎治療薬の世界市場:疫学予測

◆英語タイトル:Radiation-induced Esophagitis Epidemiology Forecast to 2030
◆商品コード:DELV20JU221
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年7月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(221名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Radiation-induced Esophagitis- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted radiation-induced esophagitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2017–2030
Radiation-induced Esophagitis: Understanding
The DelveInsight’s radiation-induced esophagitis (RIE) epidemiology report gives a thorough understanding of the RIE by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for RIE in the US, Europe, and Japan. Moreover, the report covers the detailed information of the radiation-induced esophagitis epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight:
This section encompassing radiation-induced esophagitis (RIE) epidemiology provides insights about historical and current patient pool and forecasted trend for every seven major countries. The RIE epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Detailed Epidemiology Segmentation:
The radiation-induced esophagitis epidemiology covered in the report provides historical as well as forecasted RIE epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:
The radiation-induced esophagitis (RIE) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The RIE report and model provide an overview of the global trends of RIE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report provides insight into the historical and forecasted patient pool of RIE in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report assesses the disease risk and burden and highlights the unmet needs of radiation-induced esophagitis.
The report provides the segmentation of the Radiation-induced Esophagitis epidemiology
Report Highlights:
11-year Forecast of Radiation-induced Esophagitis Epidemiology
7MM Coverage
Incidence of Lung Cancer by Types
Stage-wise Incidence of NSCLC
Cases receiving CCRT/CRT
Acute Radiation-induced Esophagitis (ARIE) by Grade
KOL – Views:
We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying theoverall scenario of the indications.

Key Questions Answered:
What will be the growth opportunities in the 7MM concerning the patient population pertaining to radiation-induced esophagitis (RIE)?
What are the key findings pertaining to the radiation-induced esophagitis (RIE) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
What would be the total number of patients of radiation-induced esophagitis (RIE) across the 7MM during the forecast period (2017–2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
What is the disease risk, burden and unmet needs of radiation-induced esophagitis (RIE)?
What are the currently available treatments of radiation-induced esophagitis (RIE)?
Reasons to buy:
The radiation-induced esophagitis (RIE) Epidemiology report will allow the user to:

Develop business strategies by understanding the trends shaping and driving the global radiation-induced esophagitis (RIE) market.
Quantify patient populations in the global radiation-induced esophagitis (RIE) market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for radiation-induced esophagitis (RIE) therapeutics in each of the markets covered
Understand the magnitude of radiation-induced esophagitis (RIE) population by its epidemiology
The radiation-induced esophagitis (RIE) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments:
Patient Segmentation
Disease Risk & Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1 Key Insights

2 Executive Summary of Radiation-induced Esophagitis (RIE)

3 SWOT Analysis for Radiation-induced Esophagitis

4 Radiation-induced Esophagitis Epidemiology Overview at a Glance

4.1 Patient Share (%) Distribution of Radiation-induced Esophagitis in 2017

4.2 Patient Share (%) Distribution of Radiation-induced Esophagitis in 2030

5 Radiation-induced Esophagitis Market Overview at a Glance

5.1 Market Share (%) Distribution of Radiation-induced Esophagitis in 2017

5.2 Market Share (%) Distribution of Radiation-induced Esophagitis in 2030

6 Disease Background and Overview

6.1 Introduction

6.2 Types

6.3 Symptoms

6.4 Grading

6.5 Pathophysiology

6.6 Diagnosis

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Total CRT Cases Suffering from ARIE in the 7MM

7.3 Assumptions and Rationale

8 Country Wise-Epidemiology of Radiation-induced Esophagitis

8.1 The United States

8.1.1 Incidence of Lung Cancer by Types in the US

8.1.2 Stage-wise Incidence of NSCLC in the US

8.1.3 Cases receiving CCRT/CRT in the US

8.1.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in the US

8.2 EU5 Countries

8.3 Germany

8.3.1 Incidence of Lung Cancer by Types in Germany

8.3.2 Stage-wise Incidence of NSCLC in Germany

8.3.3 Cases receiving CCRT/CRT in Germany

8.3.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in Germany

8.4 France

8.4.1 Incidence of Lung Cancer by Types in France

8.4.2 Stage-wise Incidence of NSCLC in France

8.4.3 Cases receiving CCRT/CRT in France

8.4.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in France

8.5 Italy

8.5.1 Incidence of Lung Cancer by Types in Italy

8.5.2 Stage-wise Incidence of NSCLC in Italy

8.5.3 Cases receiving CCRT/CRT in Italy

8.5.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in Italy

8.6 Spain

8.6.1 Incidence of Lung Cancer by Types in Spain

8.6.2 Stage-wise Incidence of NSCLC in Spain

8.6.3 Cases receiving CCRT/CRT in Spain

8.6.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in Spain

8.7 The United Kingdom

8.7.1 Incidence of Lung Cancer by Types in the UK

8.7.2 Stage-wise Incidence of NSCLC in the UK

8.7.3 Cases receiving CCRT/CRT in the UK

8.7.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in the UK

8.8 Japan

8.8.1 Incidence of Lung Cancer by Types in Japan

8.8.2 Stage-wise Incidence of NSCLC in Japan

8.8.3 Cases receiving CCRT/CRT in Japan

8.8.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in Japan

9 Treatment and Management

10 Case Study ‘ Esophageal Stricture Following Radiation, Concurrent Immunochemotherapy, Treated With Hyperbaric Oxygen and Dilation’

11 Patient Journey

12 Unmet Needs

13 Appendix

13.1 Report Methodology

14 DelveInsight Capabilities

15 Disclaimer

16 About DelveInsight

Table 1: Summary of RIE Market, Epidemiology, and Key Events (2017–2030)

Table 2: RTOG/EORTC late esophagitis morbidity grading criteria

Table 3: Normal tissue tolerance of Therapeutic Irradiation: Traditional estimates

Table 4: Total cases of Radiation-induced Esophagitis in the 7MM (2017–2030)

Table 5: Incidence of Lung Cancer by Types in the US (2017–2030)

Table 6: Stage-wise Incidence of NSCLC in the United States (2017–2030)

Table 7: Cases receiving CCRT/CRT in the United States (2017–2030)

Table 8: Acute Radiation-induced Esophagitis (ARIE) by Grade in the United States (2017–2030)

Table 9: Incidence of Lung Cancer by Types in Germany (2017–2030)

Table 10: Stage-wise Incidence of NSCLC in Germany (2017–2030)

Table 11: Cases receiving CCRT/CRT in Germany (2017–2030)

Table 12: Acute Radiation-induced Esophagitis (ARIE) by Grade in Germany (2017–2030)

Table 13: Incidence of Lung Cancer by Types in France (2017–2030)

Table 14: Stage-wise Incidence of NSCLC in France (2017–2030)

Table 15: Cases receiving CCRT/CRT in France (2017–2030)

Table 16: Acute Radiation-induced Esophagitis (ARIE) by Grade (2017–2030)

Table 17: Incidence of Lung Cancer by Types in Italy (2017–2030)

Table 18: Stage-wise Incidence of NSCLC in Italy (2017–2030)

Table 19: Cases receiving CCRT/CRT in Italy (2017–2030)

Table 20: Acute Radiation-induced Esophagitis (ARIE) by Grade in Italy (2017–2030)

Table 21: Incidence of Lung Cancer by Types in Spain (2017–2030)

Table 22: Stage-wise Incidence of NSCLC in Spain (2017–2030)

Table 23: Cases receiving CCRT/CRT in Spain (2017–2030)

Table 24: Acute Radiation-induced Esophagitis (ARIE) by Grade in Spain (2017–2030)

Table 25: Incidence of Lung Cancer by Types in the UK (2017–2030)

Table 26: Stage-wise Incidence of NSCLC in the UK (2017–2030)

Table 27: Cases receiving CCRT/CRT in the UK (2017–2030)

Table 28: Acute Radiation-induced Esophagitis (ARIE) by Grade in the UK (2017–2030)

Table 29: Incidence of Lung Cancer by Types in Japan (2017–2030)

Table 30: Stage-wise Incidence of NSCLC in Japan (2017–2030)

Table 31: Cases receiving CCRT/CRT in Japan (2017–2030)

List of Figures

 Figure 1: SWOT Analysis

Figure 2: Total cases of Radiation-induced Esophagitis in the 7MM (2017–2030)

Figure 3: Incidence of Lung Cancer by Types in the US (2017–2030)

Figure 4: Stage-wise Incidence of NSCLC in the United States (2017–2030)

Figure 5: Cases receiving CCRT/CRT in the United States (2017–2030)

Figure 6: Acute Radiation-induced Esophagitis (ARIE) by Grade in the United States (2017–2030)

Figure 7: Incidence of Lung Cancer by Types in Germany (2017–2030)

Figure 8: Stage-wise Incidence of NSCLC in Germany (2017–2030)

Figure 9: Cases receiving CCRT/CRT in Germany (2017–2030)

Figure 10: Acute Radiation-induced Esophagitis (ARIE) by Grade in Germany (2017–2030)

Figure 11: Incidence of Lung Cancer by Types in France (2017–2030)

Figure 12: Stage-wise Incidence of NSCLC in France (2017–2030)

Figure 13: Cases receiving CCRT/CRT in France (2017–2030)

Figure 14: Acute Radiation-induced Esophagitis (ARIE) by Grade in France (2017–2030)

Figure 15: Incidence of Lung Cancer by Types in Italy (2017–2030)

Figure 16: Stage-wise Incidence of NSCLC in Italy (2017–2030)

Figure 17: Cases receiving CCRT/CRT in Italy (2017–2030)

Figure 18: Acute Radiation-induced Esophagitis (ARIE) by Grade in Italy (2017–2030)

Figure 19: Incidence of Lung Cancer by Types in Spain (2017–2030)

Figure 20: Stage-wise Incidence of NSCLC in Spain (2017–2030)

Figure 21: Cases receiving CCRT/CRT in Spain (2017–2030)

Figure 22: Acute Radiation-induced Esophagitis (ARIE) by Grade in Spain (2017–2030)

Figure 23: Incidence of Lung Cancer by Types in the UK (2017–2030)

Figure 24: Stage-wise Incidence of NSCLC in the UK (2017–2030)

Figure 25: Cases receiving CCRT/CRT in the UK (2017–2030)

Figure 26: Acute Radiation-induced Esophagitis (ARIE) by Grade in the UK (2017–2030)

Figure 27: Incidence of Lung Cancer by Types in Japan (2017–2030)

Figure 28: Stage-wise Incidence of NSCLC in Japan (2017–2030)

Figure 29: Cases receiving CCRT/CRT in Japan (2017–2030)

Figure 30: Acute Radiation-induced Esophagitis (ARIE) by Grade in Japan (2017–2030)

Figure 31: Patient journey Radiation-induced Esophagitis

Figure 32: Unmet Needs of Radiation-induced Esophagitis

Figure 33: Market Drivers

Figure 34:Market Barriers

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[放射線誘発食道炎治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆